Phaseline

Companies › Sinotau Pharmaceutical Group

Sinotau Pharmaceutical Group: clinical trials, targets and expected readouts

6 active drug programs in 6 registered trials: 3 Phase 3, 2 Phase 2, 1 Phase 1; Oncology, Cardiovascular, Neurology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
XTR004
PET myocardial perfusion imaging agent
–Phase 3Coronary Artery Disease(CAD)Jun 2027
Lutetium Oxodotreotide Lu-177
Somatostatin receptor binding agent
SSTR5, SSTR2, SSTR4, SSTR1, SSTR3Phase 3Neuroendocrine TumorsDec 2028
[18F]XTR006
PET radiopharmaceutical selective for neurofibrillary tangles (NFTs)
–Phase 3Alzheimer Disease–
XTR003 Injection
PET imaging agent for myocardial fatty-acid metabolic imaging
–Phase 2Ischemic CardiomyopathyDec 2026
Lutetium[177Lu] Oxodotreotide Injection
Somatostatin receptor 2 (SSTR2)-targeting peptide receptor radionuclide therapy (PRRT) wit
SSTR2Phase 2Advanced Neuroendocrine NeoplasmJun 2027
Flotufolastat F-18 Injection
PSMA-targeted PET imaging tracer
PSMAPhase 1Prostate Cancer–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07115238[18F]XTR006Phase 3Alzheimer DiseaseNeurologyDec 2025
NCT07149831Flotufolastat F-18 InjectionPhase 1Prostate CancerOncologyDec 2025
NCT07443696XTR003 InjectionPhase 2Ischemic CardiomyopathyCardiovascularDec 2026
NCT06398444Lutetium[177Lu] Oxodotreotide InjectionPhase 2Advanced Neuroendocrine NeoplasmOncologyJun 2027
NCT07439133XTR004Phase 3Coronary Artery Disease(CAD)CardiovascularJun 2027
NCT05459844Lutetium Oxodotreotide Lu-177Phase 3Neuroendocrine TumorsOncologyDec 2028

Targets

SSTR2 (2) SSTR5 (1) SSTR4 (1) SSTR1 (1) SSTR3 (1) PSMA (1)

Companies with the same targets

Novartis HTA RayzeBio Advanced Accelerator Applications CSPC ZhongQi Pharmaceutical Technology RECORDATI GROUP ITM Solucin Debiopharm International Clarity Pharmaceuticals C Ray Therapeutics

Companies built like this

Lantheus Medical Imaging Clarity Pharmaceuticals Norroy Bioscience POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company RayzeBio

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.